ST宜化(000422.SZ)業績快報:2020年度淨利潤降28.99%至1.17億元
格隆匯 4 月 1日丨ST宜化(000422.SZ)發佈2020年度業績快報,實現營業總收入138.05億元,同比下降5.83%;利潤總額2.39億元,同比上升77.88%;歸屬於上市公司股東的淨利潤1.17億元,同比下降28.99%;基本每股收益0.13元。
報吿期內,對經營業績構成影響的主要因素如下:(1)2020年上半年,受新冠肺炎疫情影響,公司部分生產裝置停產或減負荷生產、部分企業延遲復工,對公司業績有負面影響。(2)2020年全年,主導產品聚氯乙烯、尿素、磷酸二銨市場價格先抑後揚,對公司業績有正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.